Shares in drugmaker GSK surged on Thursday after it struck a 2.2 billion US dollar (£1.68 billion) settlement to resolve tens of thousands of lawsuits in the US over its discontinued heartburn drug Zantac.
The company said it had settled with about 80,000 people who brought cases against it in the US – about 93% of all claimants – who alleged that the drug caused cancer.
The sum is seen as a major victory for GSK, after some analysts had estimated the figure would be far higher. JP Morgan’s prediction had been 3.5 billion dollars (£2.68 billion).
GSK has faced a long-running saga around Zantac, which is the brand name for the drug ranitidine.
The product reduces the amount of acid the stomach makes, and was a best-seller in the UK and US in the early 1980s in treating indigestion, heartburn and acid reflux.
It was the first drug to achieve so-called blockbuster status by generating more than a billion dollars in revenue.
But, in 2019, a laboratory in Connecticut reported that it had found “extremely high levels” of NDMA – a substance found in cigarettes and processed foods – when it heated ranitidine.
The drug was discontinued in the UK and the US as a precaution the next year. Other pharmaceutical giants like Pfizer and Sanofi have already reached settlements over similar products.
GSK has since pointed to subsequent research by the US Food and Drug Administration and the European Medicines Agency which has failed to find a causal link between the drug and cancer.
GSK did not accept any liability.
The FTSE 100 drugmaker’s share price was up 6% on Thursday morning as investors cheered the lower-than-expected settlement.
GSK said in a Wednesday evening statement that it will pay for the settlements with existing financial resources, and that it will not bring any change to the company’s “growth agenda or investment plans” for research and development.
Derren Nathan, head of equity research at Hargreaves Lansdown, added that the decision represents a “giant leap towards drawing a line under the long-running legal battle”.
He added that it is a “significantly better outcome than initially expected” and that the settlements “substantially de-risk the investment case for GSK shares which are trading at a hefty discount to the sector”.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here